Literature DB >> 9227319

Enhancement of antigen-presenting ability of B lymphoma cells by partial inhibition of protein synthesis through inducing B7-1 expression.

T Aoi1, H Nakano, Y Tanaka, T Kakiuchi.   

Abstract

During the investigation of the role of protein synthesis in antigen-presenting cell (APC) function of A20-HL B lymphoma cells, we found that partial inhibition of protein synthesis enhanced their APC function. The treatment of A20-HL cells with 0.313-2.5 microM emetine, an irreversible inhibitor of protein synthesis, decreased protein synthesis by 60-70%, and enhanced their APC function to stimulate I-Ad/OVA323-339-specific T cells to produce interleukin-2 in response to ovalbumin (OVA). The emetine-treated and paraformaldehyde-fixed A20-HL cells required only 20 nM OVA323-339 peptide to stimulate the T cells, whereas those untreated and fixed required 200 nM peptide. This enhancement of APC function was mostly because of the induction of B7-1 expression on A20-HL cells by the emetine treatment, since B7-1 molecules were detected on the emetine-treated A20-HL cells, but only negligibly, if at all, on the untreated cells, and an anti-B7-1 monoclonal antibody, 1G10, inhibited the enhanced APC function of the emetine-treated A20-HL cells. The emetine-treatment also increased B7-1 mRNA expression in A20-HL cells, suggesting that the induction of B7-1 expression was due to the increase in the accumulation of mRNA and the translation with residual ability to synthesize protein. Thus, partial inhibition of protein synthesis in A20-HL cells increases B7-1 mRNA accumulation and its expression on the cell surface, which results in the enhancement of their APC function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9227319      PMCID: PMC1363849          DOI: 10.1046/j.1365-2567.1997.00253.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  Identification of an alternatively spliced form of the murine homologue of B7.

Authors:  M Inobe; P S Linsley; J A Ledbetter; Y Nagai; M Tamakoshi; T Uede
Journal:  Biochem Biophys Res Commun       Date:  1994-04-15       Impact factor: 3.575

2.  Enhancement of inducible-type NO synthase gene transcription by protein synthesis inhibitors. Activation of an intracellular signal transduction pathway by low concentrations of cycloheximide.

Authors:  S Oguchi; A Weisz; H Esumi
Journal:  FEBS Lett       Date:  1994-02-07       Impact factor: 4.124

3.  Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.

Authors:  S Baskar; V K Clements; L H Glimcher; N Nabavi; S Ostrand-Rosenberg
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

4.  Number and evolutionary conservation of alpha- and beta-tubulin and cytoplasmic beta- and gamma-actin genes using specific cloned cDNA probes.

Authors:  D W Cleveland; M A Lopata; R J MacDonald; N J Cowan; W J Rutter; M W Kirschner
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

5.  B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.

Authors:  U Matulonis; C Dosiou; G Freeman; C Lamont; P Mauch; L M Nadler; J D Griffin
Journal:  J Immunol       Date:  1996-02-01       Impact factor: 5.422

6.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

7.  Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.

Authors:  T F Gajewski; F Fallarino; C Uyttenhove; T Boon
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

8.  Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.

Authors:  G J Freeman; F Borriello; R J Hodes; H Reiser; J G Gribben; J W Ng; J Kim; J M Goldberg; K Hathcock; G Laszlo
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

9.  Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.

Authors:  S Baskar; L Glimcher; N Nabavi; R T Jones; S Ostrand-Rosenberg
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Diversity in MHC class II antigen presentation.

Authors:  John H Robinson; Alexei A Delvig
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

2.  Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation.

Authors:  A Seo; F Ishikawa; H Nakano; H Nakazaki; K Kobayashi; T Kakiuchi
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

3.  Irradiation up-regulates CD80 expression through induction of tumour necrosis factor-alpha and CD40 ligand expression on B lymphoma cells.

Authors:  Fumio Ishikawa; Hideki Nakano; Akira Seo; Yayoi Okada; Hideko Torihata; Yuriko Tanaka; Tetsuya Uchida; Hidekazu Miyake; Terutaka Kakiuchi
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

4.  Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells.

Authors:  Hideko Torihata; Fumio Ishikawa; Yayoi Okada; Yuriko Tanaka; Tetsuya Uchida; Toru Suguro; Terutaka Kakiuchi
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.